Literature DB >> 12393031

Type1 and type2 memory T cells imbalance shown by expression of intrahepatic chemokine receptors relates to pathogenesis of primary biliary cirrhosis.

Kenichi Harada1, Koichi Tsuneyama, Mitsue Yasoshima, Yoshiko Kanemori, Hajime Ohta, Shinji Masuda, Nobuyuki Onai, Kouji Matsushima, Yasuni Nakanuma.   

Abstract

Primary biliary cirrhosis (PBC) is characterized by the immunopathologic destruction of interlobular bile ducts. Generally, immunereaction induced by the antigenetic stimulation is divided to cellular and humoral reactions, which are regulated by type1 and type2 memory T cells, respectively. The relative strength of type1 and type2 responses is an important factor in the pathophysiology of immune-mediated diseases. Chemokine receptors are disproportionally expressed in type1 and type2 T cells, providing a basis for tissue-specific recruitment of helper and cytotoxic T cell subsets. In this study, the expression of CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4), which are preferentially expressed on type1 and type2, respectively, were examined to clarify their imbalance in the PBC liver tissue (23 cases). As a control, 16 livers of chronic viral hepatitis (CVH) were used. Reverse transcription-polymerase chain reaction and semiquantitative analysis revealed that the relative ratio of CXCR3/CCR4 mRNAs was higher in early PBC (0.76+/-0.56) rather than in advanced PBC (0.25+/-0.11), and was comparable to that in active CVH (0.67+/-0.43). By immunohistochemistry, the ratio of CXCR3-/CCR4-positive mononuclear cells in portal tracts of early PBC (4.77+/-1.70) is significantly higher than that of advanced PBC (3.11+/-1.26), and also than that of mild and of active CVH. In early PBC, mononuclear cells positive for CXCR3 were dense around the damaged bile ducts. These data suggest that the enhanced shift toward type1 occurs in portal tracts of early PBC and that the imbalance of type1/type2 changes during the course of PBC. This study provides further support for the state of enhanced type1 response in early PBC and potentially offers a possibility to suppress the bile duct lesions and to prevent the progression of PBC from early to advanced stages by reversing the type1/type2 imbalance.

Entities:  

Year:  2002        PMID: 12393031     DOI: 10.1016/s1386-6346(02)00091-8

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept.

Authors:  Maria Rendina; Nicola Maurizio Castellaneta; Giuseppe Losurdo; Antonino Castellaneta; Annamaria Cazzolla; Claudia Chialà; Francesca D'Errico; Alfredo Di Leo
Journal:  Ther Adv Chronic Dis       Date:  2018-02-12       Impact factor: 5.091

Review 3.  Role of autoimmunity in primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 4.  Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis.

Authors:  Jinjung Choi; Carlo Selmi; Patrick S C Leung; Thomas P Kenny; Tania Roskams; M Eric Gershwin
Journal:  Expert Rev Clin Immunol       Date:  2016-02-25       Impact factor: 4.473

Review 5.  Molecular mechanisms of cholangiopathy in primary biliary cirrhosis.

Authors:  Kenichi Harada; Yasuni Nakanuma
Journal:  Med Mol Morphol       Date:  2006-06       Impact factor: 2.070

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.